Keywords: Health Canada, AstraZeneca, Brilinta, Merck & Co, Gardasil, Blood thinner, ACS, Anal cancer
Health Canada OKs AstraZeneca’s Brilinta and new use for Merck’s Gardasil
Article | 02 June 2011
Anglo-Swedish drug major AstraZeneca (LSE: AZN) says that Health Canada has approved Brilinta (ticagrelor tablets) for the secondary prevention of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
